Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dublin-based generics company Actavis buys US spec pharma Forest Laboratories for $23.9bn

Executive Summary

Dublin-based global generics company Actavis PLC acquired US specialty pharma Forest Laboratories Inc. in a cash and stock deal worth $23.9bn. Forest stockholders get $88.04 per share ($26.04 cash and 0.3306 Actavis shares (worth $62 based on the ten-day average)), a 29% premium.

Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies